Protocol Ledger

NCT07856329 · Phase II/III · RECRUITING

A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy

Interventional Phase II/III clinical trial protocol NCT07856329 sponsored by Genethon in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-01 Enrollment: 77 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07856329
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)77 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07856329
Protocol FieldVerified Registry Value
NCT IdentifierNCT07856329
Consolidated Lead SponsorGenethon
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment77 participants (ESTIMATED)
Registered Start Date2021-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07856329
Hospital Research SiteLocationSite Profile
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Hospital Universitario y Politécnico La FeValencia, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI